Neutropenia management with granulocyte colony-stimulating factors: from guidelines to nursing practice protocols.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  European Journal of Oncology Nursing

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.EJON.2005.08.006PMID 16207534
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• ESMO recommendations for the application of hematopoietic growth factors.

  2005cited by this paper
• Platinum-etoposide chemotherapy in elderly patients with small-cell lung cancer: results of a randomized multicenter phase II study assessing attenuated-dose or full-dose with lenograstim prophylaxis--a Forza Operativa Nazionale Italiana Carcinoma Polmonare and Gruppo Studio Tumori Polmonari Veneto

  2005cited by this paper
• First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study.

  2005cited by this paper
• Meta-analysis of prophylactic granulocyte colony-stimulating factor (G-CSF) in cancer patients receiving chemotherapy

  2005cited by this paper
• 41st Annual Meeting of the American Society of Clinical Oncology

  2005cited by this paper
• 30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study

  2005cited by this paper
• Risk models for predicting chemotherapy-induced neutropenia.

  2005cited by this paper
• Are prophylactic haematopoietic growth factors of value in the management of patients with aggressive non-Hodgkin's lymphoma?

  2004cited by this paper
• Family caring strategies in neutropenia.

  2004cited by this paper
• Increased risk of myelotoxicity in elderly patients with non‐Hodgkin lymphoma

  2004cited by this paper
• Costs of human resources in delivering cancer chemotherapy and managing chemotherapy-induced neutropenia in community practice

  2004cited by this paper
• Medical visits for chemotherapy and chemotherapy-induced neutropenia: a survey of the impact on patient time and activities

  2004cited by this paper
• The hidden costs of cancer care: an overview with implications and referral resources for oncology nurses.

  2004cited by this paper
• Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study.

  2004cited by this paper
• Pegfilgrastim.

  2003cited by this paper
• The impact of frequent injections for hematopoietic growth factor support on patients receiving chemotherapy: an observational study

  2003cited by this paper
• A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy.

  2003cited by this paper
• Delivering optimal adjuvant chemotherapy in primary breast cancer: the role of rHuG-CSF

  2003cited by this paper
• EORTC Cancer in the Elderly Task Force guidelines for the use of colony-stimulating factors in elderly patients with cancer.

  2003cited by this paper
• Impact of Long‐Acting Growth Factors on Practice Dynamics and Patient Satisfaction

  2003cited by this paper
• Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices.

  2003cited by this paper
• Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer.

  2002cited by this paper
• Delivering adjuvant chemotherapy to women with early‐stage breast carcinoma

  2001cited by this paper
• Patterns of chemotherapy administration in patients with intermediate-grade non-Hodgkin's lymphoma.

  2001cited by this paper
• 'More than just money' -- widening the understanding of the costs involved in cancer care.

  2001cited by this paper
• 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel.

  2000cited by this paper
• The impact of travel on cancer patients' experiences of treatment: a literature review.

  2000cited by this paper
• Breast cancer patients' out-of-pocket expenses.

  1999cited by this paper
• Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B.

  1998cited by this paper
• Outpatient chemotherapy: telephone triage for symptom management.

  1997cited by this paper
• Dose intensity of standard adjuvant CMF with granulocyte colony-stimulating factor for premenopausal patients with node-positive breast cancer.

  1996cited by this paper
• Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer.

  1994cited by this paper
• Determinants of cancer therapy in elderly patients

  1993cited by this paper
• Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy.

  1993cited by this paper
• Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy.

  1993cited by this paper
• Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: application to LNH-87 protocol. The GELA. (Groupe d'Etude des Lymphomes de l'Adulte).

  1993cited by this paper
• The costs of treating febrile neutropenia in six U.K. Hospitals.

  1993cited by this paper
• Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer

  1991cited by this paper
• Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis.

  1990cited by this paper
• Survival of diffuse large cell lymphoma. A multivariate analysis including dose intensity variables

  1990cited by this paper
• Empiric antibiotic therapy for granulocytopenic cancer patients.

  1986cited by this paper
• Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: the Southwest Oncology Group experience.

  1986cited by this paper
• Empiric antibiotic therapy for granulocytopenic cancer patients.

  1986cited by this paper
• Proceedings of the American Society of Clinical Oncology

  1982cited by this paper
• Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia.

  1966cited by this paper

• Incidence and Factors Influencing Neutropenia in Patients with Chemotherapy

  2018cites this paper
• Effects of granulocyte colony-stimulating factor administration time on pain.

  2017cites this paper
• Effectiveness of a Nursing Intervention Protocol for Chemotherapy Induced Neutropenia : Nurses and Patients ’ Related Outcome

  2016cites this paper
• A semiquinone glucoside derivative isolated from Bacillus sp. INM-1 provides protection against 5-fluorouracil-induced immunotoxicity

  2015cites this paper
• Neutropenia: occurrence and management in women with breast cancer receiving chemotherapy

  2014cites this paper
• Febrile neutropenia risk assessment tool: improving clinical outcomes for oncology patients.

  2014cites this paper
• Neutropenia e qualidade de vida em mulheres com câncer de mama durante o tratamento quimioterápico

  2012cites this paper
• Managing neutropenia in older patients with cancer receiving chemotherapy in a community setting.

  2010cites this paper
• ـــــ IMPACT OF IMPLEMENTING OF EVIDENCE-BASED NURSING INTERVENTION PROTOCOL ON NURSE'S KNOWLEDGE AND PRACTICES AS WELL AS ON PATIENT'S OUTCOMES RELATED TO CHEMOTHERAPY INDUCED NEUTROPENIA AMONG CANCER PATIENTS, ASSIUT UNIVERSITY HOSPITALS

  2009cites this paper
• Élaboration d'outils pour informer les professionnels de santé de ville sur la prise en charge des effets indésirables des anticancéreux par voie orale

  2008cites this paper
• Myeloprotective effects of rosiglitazone, an insulin sensitizer, on 5-fluorouracil-induced toxicity

  2007cites this paper
• Granulocyte colony stimulating factors

  2007influential citation
• Risks and consequences of chemotherapy-induced neutropenia.

  2006cites this paper
• An analysis of current neutropenia therapies, including pegfilgrastim.

  2006cites this paper
• Nursing as the cornerstone of effective supportive care for patients with cancer.

  2005cites this paper